Exclusive Papers from the Editorial Board Members (EBMs) of Neurology International
    
    
        Share This Topical Collection
        
     
             Editor
        
                
    
        
                    
         Prof. Dr.             Junji Yamauchi
             Prof. Dr.             Junji Yamauchi
         
    
         Prof. Dr.             Junji Yamauchi
             Prof. Dr.             Junji Yamauchi
         
    
 
        
        
        
        
                    E-Mail
        
                                            Website
                    
        
                            Collection Editor
             
    
    
        1. Laboratory of Molecular Neurology, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan
2. Department of Pharmacology, National Research Institute for Child Health and Development, Tokyo, Japan
        
Interests: molecular mechanisms underlying myelination and demyelination; molecular and cellular therapeutic procedures for Charcot–Marie–Tooth diseases; Pelizaeus–Merzbacher disease and hypomyelinating leukodystrophies; frontotemporal dementia        
                                                                                                                
                                    
Special Issues, Collections and Topics in MDPI journals
                    
                                          
         
    
    Topical Collection Information
    
        Dear Colleagues,
As the Editor in Chief of Neurology International, I am pleased to announce the creation of a Topical Collection titled “Exclusive Papers from the Editorial Board Members (EBMs) of Neurology International”. This will be a collection of high-quality research works of the Editorial Board Members of Neurology International. The aim of this Topical Collection is to provide a platform for networking and communication between members of this journal and scholars in its related field.
We welcome both original research articles and comprehensive review papers that address current critical issues in the field, which are grounded in sound science, and which provide authoritative commentaries, as well as those presenting novel concepts. All manuscripts will be published and made fully open access following successful peer review.
Prof. Dr. Junji Yamauchi
Collection Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the collection website.  Research articles, review articles as well as short communications are invited.   For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a  single-blind   peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Neurology International is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript.
 The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs).
Submitted papers should be well formatted and use good English. Authors may use MDPI's
English editing service prior to publication or during author revisions.
     
    Keywords
    
- stroke
- multiple sclerosis
- movement disorders
- neurooncology epilepsy
- neurorehabilitation
- neurointensive care
- neuroinfectious disorders
- neurometabolic disorders
- headache
- other neurological pain syndromes
- sleep disorders
- traumatic disorders
- neuropathies
- cognition
- neurobehavior
- neurosurgery
 
        
            Published Papers (2 papers) 
         
                    
             
    
	        	       
                    
            
2025
                    
                            
                
        
        
                    
    
        Open AccessArticle
    
    The Effects of Co-Culturing ND7/23 Sensory Neuron-like Cells and IFRS1 Schwann Cells on Myelination: A Single-Arm Nonrandomized Study
                        
            by
                    Shizuka Takaku and Kazunori Sango        
    
                
        
                        Viewed by 3435    
    
                    
        
                    Abstract 
            
            
            Background/Objectives: Co-culture models of neurons and Schwann cells have been used to explore the mechanisms of myelination during development, axonal regeneration after injury, and the pathogenesis of various demyelinating neuropathies. A spontaneously immortalized Fischer rat Schwann cell line 1 (IFRS1), established from
            
 [...] Read more.
         
        
            Background/Objectives: Co-culture models of neurons and Schwann cells have been used to explore the mechanisms of myelination during development, axonal regeneration after injury, and the pathogenesis of various demyelinating neuropathies. A spontaneously immortalized Fischer rat Schwann cell line 1 (IFRS1), established from the primary culture of adult Fischer344 rat peripheral nerves, can myelinate neurites in co-cultures with primary cultured dorsal root ganglion neurons and neuronal cell lines, such as nerve growth factor (NGF)-primed PC12 cells and NSC-34 motor neuron-like cells. In this study, we aimed to establish a stable co-culture system using IFRS1 cells and ND7/23 sensory neuron-like cells. 
Methods: ND7/23 cells were seeded at a low density (2 × 10
3/cm
2) and maintained for 7 days in serum-containing medium supplemented with NGF (10 ng/mL) and the Rho kinase inhibitor Y27632 (5 μM) to promote neurite elongation. The cells were then treated with the anti-mitotic agent mitomycin C (1 μg/mL) for 12–16 h to suppress proliferative activity. Following this, the cells were co-cultured with IFRS1 cells (2 × 10
4/cm
2) and maintained at 37 °C in serum-containing medium supplemented with ascorbic acid (50 μg/mL), NGF (10 ng/mL), and ciliary neurotrophic factor (10 ng/mL). 
Results: Double-immunofluorescence staining performed on day 21 of the co-culture revealed myelin protein 22- or myelin basic protein-immunoreactive IFRS1 cells surrounding βIII tubulin-immunoreactive neurites emerging from ND7/23 cells. Myelin formation was further confirmed via Sudan Black B staining and electron microscopy. 
Conclusions: This co-culture system may provide a valuable tool for studying the processes of myelination in the peripheral nervous system, as well as the pathogenesis of various sensory neuropathies and potential novel therapeutic approaches for these conditions.
            
Full article
         
     
        
        
►▼
             Show Figures
              
             
                    
                
                
    
        
                    
    
        Open AccessArticle
    
    The Association of Axonal Damage Biomarkers and Osteopontin at Diagnosis Could Be Useful in Newly Diagnosed MS Patients
                        
            by
                    Eleonora Virgilio, Chiara Puricelli, Nausicaa Clemente, Valentina Ciampana, Ylenia Imperatore, Simona Perga, Sveva Stangalini, Elena Boggio, Alice Appiani, Casimiro Luca Gigliotti, Umberto Dianzani, Cristoforo Comi and Domizia Vecchio        
    
                
        
                        Viewed by 625    
    
                    
        
                    Abstract 
            
            
            (1) Background: Multiple sclerosis (MS) is a biologically highly heterogeneous disease and has poor predictability at diagnosis. Moreover, robust data indicate that early disease activity strongly correlates with future disability. Therefore, there is a need for strong and reliable biomarkers from diagnosis to
            
 [...] Read more.
        
            (1) Background: Multiple sclerosis (MS) is a biologically highly heterogeneous disease and has poor predictability at diagnosis. Moreover, robust data indicate that early disease activity strongly correlates with future disability. Therefore, there is a need for strong and reliable biomarkers from diagnosis to characterize and identify patients who require highly effective disease-modifying treatments (DMTs). Several biomarkers are promising, particularly neurofilament light chains (NFLs), but the relevance of others is less consolidated. (2) Methods: We evaluated a panel of axonal damage and inflammatory biomarkers in cerebrospinal fluid (CSF) and matched serum obtained from a cohort of 60 newly diagnosed MS patients. Disability at diagnosis, negative prognostic factors, and the initial DMT prescribed were carefully recorded. (3) Results: We observed correlations between different axonal biomarkers: CSF and serum NFL versus CSF total tau; and between the inflammatory marker osteopontin (OPN) and axonal biomarkers CSF p-Tau, CSF total tau, and serum NFL. CSF and serum NFL and total tau, as well as CSF OPN, positively correlated with EDSS at diagnosis. Moreover, CSF and serum NFL levels were increased in patients with gadolinium-enhancing lesions (
p = 0.01 and 
p = 0.04, respectively) and in those treated with highly effective DMT (
p = 0.049). Furthermore, CSF OPN and both CSF and serum NFL levels significantly differentiated patients based on EDSS, with a combined ROC AUC of 0.88. We calculated and internally validated biomarker (in particular serum NFL) thresholds that significantly identified patients with higher disability. Finally, CSF OPN levels and dissemination in the spinal cord were significant predictors of EDSS at diagnosis. (4) Conclusions: These preliminary exploratory data confirm the pathological interconnection between inflammation and axonal damage from early disease stages, contributing to early disability. Follow-up data, such as longitudinal disability scores, repeated serum measurements, a healthy control group, and external validation of our results, are needed. We suggest that combining several fluid biomarkers may improve the clinical characterization of patients.
            
Full article
         
        
        
►▼
             Show Figures